LYON, France, March 28, 2024 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , announces the publication, at the end of April 2024, of its 2023 annual results, initially scheduled for April 9, 2024, taking into account the expected conclusion of a transaction by the end of April.
The Company, having made significant progress in its search for additional financing, aims, by the end of April, to conclude an agreement relating to the monetization of royalties from sales of TWYMEEG® (Imeglimin) in Japan.
Poxel expects that its financial resources will be sufficient to maintain its operations until the completion of this monetization transaction.
The Company will communicate its new financial calendar for the month of April 2024, as soon as this operation is finalized.
To receive information from POXEL in real time, send a request to [email protected].